Identifying tumor molecules for early pancreatic cancer detection
Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions
This study is trying to find specific molecules in tumors that can help detect pancreatic cancer earlier and more easily for people who might be at risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hull University Teaching Hospitals NHS Trust Government |
| Locations | 1 site (Cottingham, Kingston Upon Hull) |
| Trial ID | NCT03536793 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the early detection of pancreatic cancer by investigating various tumor regulatory molecules. The focus is on identifying markers that can signal the presence of pancreatic cancer or pre-cancerous cysts, which are often difficult to diagnose due to a lack of specific symptoms. By studying these molecules, the researchers hope to develop a less invasive and more effective screening method that could lead to earlier surgical intervention and better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with localized pancreatic cancer or cystic lesions that require further diagnostic intervention.
Not a fit: Patients with advanced pancreatic cancer that is not amenable to surgical resection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly enhance the early detection of pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Other studies have explored similar approaches in cancer detection, but the specific focus on tumor regulatory molecules in pancreatic cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: General * Capable of giving written informed consent * Age ≥18 years Pancreatic Cancer Cohort \- Diagnosed with localised pancreatic cancer amenable to resection (distal pancreatectomy, total pancreatectomy or Whipple's procedure). OR - Diagnosed with inoperable localised pancreatic cancer and referred for further management (malignant control subgroup). Pancreatic Cysts Cohort \- Presence of cystic lesions where MDT have agreed further diagnostic intervention procedures (including FNA/EUS) necessary. OR - Patient the MDT have agreed have resectable lesions suspicious for pancreatic malignancy and going to surgery. Benign Cohort \- Referral for endoscopic cystogastrostomy for complicated acute pancreatitis characterised by peripancreatic fluid collections and pseudocysts in development or matured (non-resolving and requiring further intervention). OR * Referral for cholecystectomy for cholocystitis/chololethiasis. OR * Patient planned to have endoscopy investigation for dyspepsia (normal control subgroup). Exclusion Criteria: General * Inability to provide written informed consent * Other known malignant condition, either active or in complete remission ≤5 years * HIV, hepatitis C, or any other known communicable disease
Where this trial is running
Cottingham, Kingston Upon Hull
- Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust — Cottingham, Kingston Upon Hull, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Anthony Maraveyas — Hull University Teaching Hospitals NHS Trust
- Study coordinator: Anthony Maraveyas
- Email: anthony.maraveyas@nhs.net
- Phone: 01482 461245
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.